Fly News Breaks for January 7, 2020
SRPT, PCRX, PTGX
Jan 7, 2020 | 07:50 EDT
Sarepta Therapeutics (SRPT), Pacira Biosciences (PCRX) and Protagonist Therapeutics (PGTX) are BTIG's top Biotech picks for 2020, analyst Timothy Chiang tells investors in a research note. He believes Sarepta shares have the potential for "significant outperformance" in the next 12 months based on expected initiation of its commercial supply study with SRP-9001 for the treatment of patients with Duchenne Muscular Dystrophy by mid-2020 and increased visibility on its other gene therapy programs. Pacira shares could be an outperformer in 2020 based on Exparel's "strong momentum," Chiang writes. Meanwhile, shares of Protagonist are "poised to recover" in 2020 with multiple potential data readouts expected. The company has multiple shots on goal with its key pipeline candidates entering Phase 2 studies, including PN-943 in inflammatory bowel disease and PTG-300 for the treatment of beta-thalassemia, polycythemia vera, hereditary hemochromatosis and myelodystplastic syndrome, contends Chiang. He keeps Buy ratings on all three names.
News For SRPT;PCRX;PTGX From the Last 2 Days
There are no results for your query SRPT;PCRX;PTGX